Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-1-12
pubmed:abstractText
Limited data are available on Chryseobacterium spp. leading to an evaluation of the patient demographics and susceptibility patterns for Chryseobacterium spp. collected in the first 5 years of the SENTRY Antimicrobial Surveillance Program (1997 to 2001). Fifty isolates (24 Chryseobacterium meningosepticum, 20 Chryseobacterium indologenes, two Chryseobacterium gleum, and 4 Chryseobacterium spp. isolates) were collected. The highest Chryseobacterium prevalence was detected among the elderly. The most active antimicrobials were the newer quinolones (garenoxacin, gatifloxacin, and levofloxacin, each with a MIC at which 90 percent of the isolates are inhibited [MIC(90)] of 1 micro g/ml and 98.0% susceptibility) followed by rifampin (MIC(90), 2 microg/ml and 85.7% susceptibility). Trimethoprim-sulfamethoxazole, ciprofloxacin, and piperacillin-tazobactam also showed reasonable activity; vancomycin showed poor potency.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-10471563, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-10858348, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-11036018, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-11158734, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-11226658, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-11247678, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-11531991, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-11897576, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-12084101, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-12578312, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-3455909, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-511985, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-6563023, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-708026, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-7494007, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-8645856, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-9064486, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-9210666, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-9210669, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-9323467, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-9420049, http://linkedlifedata.com/resource/pubmed/commentcorrection/14715802-9597247
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0095-1137
pubmed:author
pubmed:issnType
Print
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
445-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).
pubmed:affiliation
The Jones Group/JMI Laboratories, North Liberty, Iowa, USA.
pubmed:publicationType
Journal Article